Chong‐Jen Yu

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +15

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib

James Bean, Cameron Brennan, Jin‐Yuan Shih et al. · Proceedings of the National Academy of Sciences · 2007 · 1.6K citations

Medicine, Genetics, Oncology +17

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +14

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater et al. · The Lancet Oncology · 2015 · 982 citations

Medicine, Oncology, Pharmacology +16

Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia

Guangchang Pei, Zhiguo Zhang, Jing Peng et al. · Journal of the American Society of Nephrology · 2020 · 817 citations · Full text

Medicine, Infectious Diseases, Nephrology +12